Managers / Q2 2019 · view latest →
FRAZIER MANAGEMENT LLC
CIK 0001032165 · 601 UNION ST, SUITE 2110, SEATTLE, WA, 98101 · 2066217200
Summary
Frazier Management LLC reported $390M in U.S.-listed holdings across 18 positions for Q2 2019.
The portfolio is heavily concentrated: ANAB alone accounts for 33.5% of reported value.
Compared with Q1 2019, the fund opened 1 new position and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 76.1% · $297M
- Other · 23.9% · $93M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| TRANSLATE BIO INC | NEW | +1.68M | 1.68M | +$21M | $21M |
| KEZAR LIFE SCIENCES INC | ADDED | +97.7K | 467.7K | −$3M | $4M |
| KRYSKRYSTAL BIOTECH INC | HELD | +20.0K | 895.0K | +$7M | $36M |
| ANABANAPTYSBIO INC | HELD | +0 | 2.32M | −$39M | $131M |
| IOVAIOVANCE BIOTHERAPEUTICS INC | HELD | +0 | 2.19M | +$33M | $54M |
| ALLENA PHARMACEUTICALS INC | HELD | +0 | 3.33M | −$10M | $14M |
| SIERRA ONCOLOGY INC | HELD | +0 | 8.11M | −$9M | $5M |
| ALPINE IMMUNE SCIENCES INC | HELD | +0 | 2.57M | −$7M | $11M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ANABANAPTYSBIO INChistory → | COM | 33.49% | $131M | 2.32M |
| 2 | IOVAIOVANCE BIOTHERAPEUTICS INChistory → | COM | 13.75% | $54M | 2.19M |
| 3 | KRYSKRYSTAL BIOTECH INChistory → | COM | 9.24% | $36M | 895.0K |
| 4 | COLLCOLLEGIUM PHARMACEUTICAL INChistory → | COM | 6.36% | $25M | 1.89M |
| 5 | GRITSTONE ONCOLOGY INC | COM | 5.89% | $23M | 2.06M |
| 6 | TRANSLATE BIO INC | COM | 5.45% | $21M | 1.68M |
| 7 | MILLENDO THERAPEUTICS INC | COM | 4.14% | $16M | 1.40M |
| 8 | ALLENA PHARMACEUTICALS INC | COM | 3.47% | $14M | 3.33M |
| 9 | ALPINE IMMUNE SCIENCES INC | COM | 2.77% | $11M | 2.57M |
| 10 | APTINYX INC | COM | 2.73% | $11M | 3.19M |
| 11 | ITERUM THERAPEUTICS PLC | SHS | 2.71% | $11M | 1.54M |
| 12 | NABRIVA THERAPEUTICS PLC | SHS | 2.65% | $10M | 4.26M |
| 13 | ENTASIS THERAPEUTICS HLDGS I | COM | 2.23% | $9M | 1.35M |
| 14 | SYNLOGIC INC | COM | 2.02% | $8M | 865.4K |
| 15 | SIERRA ONCOLOGY INC | COM | 1.16% | $5M | 8.11M |
| 16 | KEZAR LIFE SCIENCES INC | COM | 0.92% | $4M | 467.7K |
| 17 | CIDARA THERAPEUTICS INC | COM | 0.57% | $2M | 1.31M |
| 18 | BELLICUM PHARMACEUTICALS INC | COM | 0.46% | $2M | 1.05M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2022 | $0 | 1 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $1M | 1 | Aug 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | Under review | 2 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $1.3B | 43 | Feb 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.2B | 41 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $1.1B | 34 | Aug 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $1.2B | 35 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $1.3B | 35 | Feb 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $1.1B | 31 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $1.1B | 26 | Aug 4, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $882M | 25 | May 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $596M | 20 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $320M | 19 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $390M | 18 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $415M | 17 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $388M | 17 | Feb 11, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.